Veru Inc
VERU2.340USD
+0.020+0.86%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
34.28MMarket Cap
LossP/E TTM
More Details of Veru Inc Company
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Veru Inc Info
Ticker SymbolVERU
Company nameVeru Inc
IPO dateJul 19, 1990
CEOSteiner (Mitchell S)
Number of employees210
Security typeOrdinary Share
Fiscal year-endJul 19
Address2916 N. Miami Avenue
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33127
Phone13125959123
Websitehttps://verupharma.com/
Ticker SymbolVERU
IPO dateJul 19, 1990
CEOSteiner (Mitchell S)
Company Executives of Veru Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Harry Fisch, M.D.
Dr. Harry Fisch, M.D.
Vice Chairman of the Board, Chief Corporate Officer
Vice Chairman of the Board, Chief Corporate Officer
801.38K
--
Mr. Michael L. Rankowitz
Mr. Michael L. Rankowitz
Independent Director
Independent Director
25.00K
--
Mr. Loren Mark Katzovitz
Mr. Loren Mark Katzovitz
Independent Director
Independent Director
22.40K
--
Ms. Michele Greco, CPA
Ms. Michele Greco, CPA
Chief Financial Officer, Chief Administrative Officer
Chief Financial Officer, Chief Administrative Officer
9.62K
--
Ms. Grace Hyun, M.D.
Ms. Grace Hyun, M.D.
Independent Director
Independent Director
1.48K
--
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
980.00
--
Mr. Samuel Fisch
Mr. Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Executive Director, Investor Relations and Corporate Communications
--
--
Dr. Mitchell S. (Mitch) Steiner, M.D.
Dr. Mitchell S. (Mitch) Steiner, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. K. Gary Barnette, Ph.D.
Dr. K. Gary Barnette, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Harry Fisch, M.D.
Dr. Harry Fisch, M.D.
Vice Chairman of the Board, Chief Corporate Officer
Vice Chairman of the Board, Chief Corporate Officer
801.38K
--
Mr. Michael L. Rankowitz
Mr. Michael L. Rankowitz
Independent Director
Independent Director
25.00K
--
Mr. Loren Mark Katzovitz
Mr. Loren Mark Katzovitz
Independent Director
Independent Director
22.40K
--
Ms. Michele Greco, CPA
Ms. Michele Greco, CPA
Chief Financial Officer, Chief Administrative Officer
Chief Financial Officer, Chief Administrative Officer
9.62K
--
Ms. Grace Hyun, M.D.
Ms. Grace Hyun, M.D.
Independent Director
Independent Director
1.48K
--
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
980.00
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
FC2
16.89M
0.00%
ENTADFI
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
5.35M
31.71%
Other Countries
4.70M
27.81%
Brazil
2.76M
16.35%
Mozambique
2.17M
12.87%
South Africa
1.90M
11.26%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
FC2
16.89M
0.00%
ENTADFI
0.00
0.00%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fisch (Harry)
4.99%
Steiner (Mitchell Shuster)
4.42%
The Vanguard Group, Inc.
3.99%
Sheets Smith Investment Management, LLC
2.01%
Osaic Holdings, Inc.
1.62%
Other
82.97%
Shareholders
Shareholders
Proportion
Fisch (Harry)
4.99%
Steiner (Mitchell Shuster)
4.42%
The Vanguard Group, Inc.
3.99%
Sheets Smith Investment Management, LLC
2.01%
Osaic Holdings, Inc.
1.62%
Other
82.97%
Shareholder Types
Shareholders
Proportion
Investment Advisor
14.72%
Individual Investor
9.78%
Hedge Fund
4.54%
Investment Advisor/Hedge Fund
2.05%
Research Firm
0.69%
Bank and Trust
0.05%
Other
68.17%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
240
4.28M
29.19%
-3.53M
2025Q2
251
66.80M
45.57%
-33.46M
2025Q1
283
69.84M
47.66%
-32.47M
2024Q4
295
79.36M
54.21%
-33.45M
2024Q3
309
82.19M
56.15%
-33.59M
2024Q2
326
82.55M
56.40%
-32.46M
2024Q1
334
70.85M
48.86%
-37.80M
2023Q4
330
80.47M
66.79%
+16.27M
2023Q3
322
34.44M
38.13%
-32.79M
2023Q2
333
37.33M
42.39%
-37.59M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fisch (Harry)
801.38K
5.47%
--
--
May 28, 2025
Steiner (Mitchell Shuster)
708.67K
4.83%
--
--
May 28, 2025
The Vanguard Group, Inc.
640.69K
4.37%
+15.58K
+2.49%
Jun 30, 2025
Millennium Management LLC
262.15K
1.79%
+260.65K
+17411.62%
Jun 30, 2025
Oppenheimer Asset Management Inc.
131.30K
0.9%
-1.22K
-0.92%
Jun 30, 2025
PVG Asset Management Corporation
164.74K
1.12%
+5.05K
+3.16%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 06, 2025
Merger
10→1
Date
Type
Ratio
Aug 06, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Veru Inc?
The top five shareholders of Veru Inc are:
Fisch (Harry) holds 801.38K shares, accounting for 5.47% of the total shares.
Steiner (Mitchell Shuster) holds 708.67K shares, accounting for 4.83% of the total shares.
The Vanguard Group, Inc. holds 640.69K shares, accounting for 4.37% of the total shares.
Millennium Management LLC holds 262.15K shares, accounting for 1.79% of the total shares.
Oppenheimer Asset Management Inc. holds 131.30K shares, accounting for 0.90% of the total shares.
Fisch (Harry) holds 801.38K shares, accounting for 5.47% of the total shares.
Steiner (Mitchell Shuster) holds 708.67K shares, accounting for 4.83% of the total shares.
The Vanguard Group, Inc. holds 640.69K shares, accounting for 4.37% of the total shares.
Millennium Management LLC holds 262.15K shares, accounting for 1.79% of the total shares.
Oppenheimer Asset Management Inc. holds 131.30K shares, accounting for 0.90% of the total shares.
What are the top three shareholder types of Veru Inc?
The top three shareholder types of Veru Inc are:
Fisch (Harry)
Steiner (Mitchell Shuster)
The Vanguard Group, Inc.
Fisch (Harry)
Steiner (Mitchell Shuster)
The Vanguard Group, Inc.
How many institutions hold shares of Veru Inc (VERU)?
As of 2025Q3, 240 institutions hold shares of Veru Inc, with a combined market value of approximately 4.28M, accounting for 29.19% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -16.38%.
What is the biggest source of revenue for Veru Inc?
In FY2024, the FC2 business generated the highest revenue for Veru Inc, amounting to 16.89M and accounting for --% of total revenue.
